Helen Kalirai

Dr. Helen Kalirai


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2014 in British Journal of Cancer
Verified
Journal Article
Open access
HKHelen Kalirai
Helen Kalirai
ADA Dodson
A Dodson
SFS Faqir
S Faqir
BDB E Damato
B E Damato
Sarah E. CouplandSarah E. Coupland
Sarah E. Coupland
The absence of BRCA1-associated protein 1 (BAP1) expression in uveal melanoma (UM) is associated with metastatic progression and reduced survival. In this study, we examine nuclear BAP1 (nBAP1) protein expression in primary UMs (PUMs) that show both 'typical' and 'atypical' clinical courses according to their chromosome 3 status, and secondary hepatic metastatic UM (MUM), correlating the results with histological, clinical and survival data. Nuclear BAP1 expression was immunohistochemically assessed in tissue microarrays (TMAs) of: (a) 68 PUM patients, who had been treated surgically; and (b) 13 MUM patients, with 5 cases being paired with primary tumour tissue. All cases were fully annotated. The percentage of tumour cell nuclei staining positively for BAP1 was scored by independent observers. Nuclear BAP1 protein expression was absent in 35 out of 68 (51%) PUM patients, correlating strongly with poor prognostic clinicopathological and genetic parameters and reduced survival (Log rank, P<0.001). Lack of nBAP1 expression importantly identified a subset of 'atypical' PUM patients with disomy of chromosome 3 but with unexpected metastatic relapse. Nuclear BAP1 expression was absent in 10 out of 13 (77%) MUM and expression was concordant in all paired PUM and MUM patients. Absent nBAP1 protein expression is an independent survival predictor for UM patients, easily examined using immunohistochemistry.

23 April 2020 in Cancers
Verified
Journal Article
Open access
STSophie Thornton
Sophie Thornton
Sarah E. CouplandSarah E. Coupland
Sarah E. Coupland
LOLisa Olohan
Lisa Olohan
JSJulie Sibbring
Julie Sibbring
JKJohn Kenny
John Kenny
HKHelen Kalirai
Helen Kalirai
Uveal melanoma (UM) has well-characterised somatic copy number alterations (SCNA) in chromosomes 1, 3, 6 and 8, in addition to mutations in GNAQ, GNA11, CYSLTR2, PLCB4, BAP1, SF3B1 and EIF1AX, most being linked to metastatic-risk. To gain further insight into the molecular landscape of UM, we designed a targeted next-generation sequencing (NGS) panel to detect SCNA and mutations in routine clinical UM samples. We compared hybrid-capture and amplicon-based target enrichment methods and tested a larger cohort of primary UM samples on the best performing panel. UM clinical samples processed either as fresh-frozen, formalin-fixed paraffin embedded (FFPE), small intraocular biopsies or following irradiation were successfully profiled using NGS, with hybrid capture outperforming the PCR-based enrichment methodology. We identified monosomy 3 (M3)-UM that were wild-type for BAP1 but harbored SF3B1 mutations, novel frameshift deletions in SF3B1 and EIF1AX, as well as a PLCB4 mutation outside of the hotspot on exon 20 coinciding with a GNAQ mutation in some UM. We observed samples that harboured mutations in both BAP1 and SF3B1, and SF3B1 and EIF1AX, respectively. Novel mutations were also identified in TTC28, KTN1, CSMD1 and TP53BP1. NGS can simultaneously assess SCNA and mutation data in UM, in a reliable and reproducible way, irrespective of sample type or previous processing. BAP1 and SF3B1 mutations, in addition to 8q copy number, are of added importance when determining UM patient outcome.

1 April 2015 in Ocular Oncology and Pathology
Verified
Journal Article
Open access
PDF file
HKHelen Kalirai
Helen Kalirai
HSHaleh Shahidipour
Haleh Shahidipour
Sarah E. CouplandSarah E. Coupland
Sarah E. Coupland
GLGregorius Luyten
Gregorius Luyten
Animal models play a crucial role in basic and translational oncology research. Conventional rodent experiments, however, face ethical, practical and technical issues that limit their use. The chick embryo represents an accessible and economical in vivo model, which has long been used in developmental biology and for the study of angiogenesis. It is also a recognised xenograft model, and because of its lack of immune system in early development, the chick embryo has established itself as a key model system for cancer research, with which to study various steps in the metastatic process. In this chapter, we review the chick embryo model and the technical approaches adopted by cancer biologists, including advances in real-time imaging, and discuss how this has been or can be applied to improve our understanding of the biological events during uveal melanoma development and metastasis.

29 March 2018 in Impact
Verified
Journal Article
Closed access
Sergio Roman-RomanSergio Roman-Roman
Sergio Roman-Roman
MSMarc-Henri Stern
Marc-Henri Stern
SASamar Alsafadi
Samar Alsafadi
MJMartine J. Jager
Martine J. Jager
MDMehmet Dogrusöz
Mehmet Dogrusöz
EVEmilie Vinolo
Emilie Vinolo
Uveal melanoma (UM) is a rare intraocular tumour with an incidence of 5 cases per million individuals per year. Up to 50% of UM patients develop metastases, most often in the liver, and these are invariably fatal. Despite new discoveries in the genetic and molecular background of the primary tumour, little is known about the metastatic disease; furthermore, there is no therapy to either prevent or treat UM metastases. In UM Cure 2020, we aim to identify and validate at the preclinical level novel therapeutic approaches for the treatment of UM metastases. For this purpose, the consortium brings together the major experts of UM in both patient care and basic/translational/clinical research, as well as patient representatives. An ambitious multidisciplinary approach is proposed to move from patient tissue characterisation to preclinical evaluation of single or combinations of drugs. This approach includes the characterisation of the genetic landscape of metastatic UM and its microenvironment, proteomic studies to address signal pathway deregulation and establishment of novel relevant in vitro and in vivo UM models. We also aim to validate accurate surrogate endpoint biomarkers to evaluate therapies and detect metastases as early as possible. Underpinning this will be the UM Cure 2020 virtual biobank registry, linking existing biobanks into a harmonised network, which will prospectively collect primary and metastatic UM samples. Together, our approach will lead to the identification of new therapies, allowing the initiation of UM-dedicated clinical trials sponsored by academia or pharma. Dissemination of results will include the building of a patient network across the countries as part of the consortium as well as a dedicated UM patient and caregiver's data portal as part of the UM Cure 2020 website, in order to increase patient information and disease awareness.

10 June 2014 in The Journal of OncoPathology
Verified
Journal Article
Closed access
SLSarah L. Lake
Sarah L. Lake
HKHelen Kalirai
Helen Kalirai
BDBertil E. Damato
Bertil E. Damato
Sarah E. CouplandSarah E. Coupland
Sarah E. Coupland

19 September 2012
Verified
Book Chapter
Closed access
PDF file
HKHelen Kalirai
Helen Kalirai
BDBertil E. Damato
Bertil E. Damato
SCSarah E. Coupland
Sarah E. Coupland